curriculum vitae michael v. drake, m.d. · 1 day ago · curriculum vitae . michael v. drake, m.d....

Drake, Michael - CV.doc

CURRICULUM VITAE Michael V. Drake, M.D.

EMPLOYMENT HISTORY: President, The Ohio State University 2014-present Chancellor, University of California, Irvine 2005-2014 Distinguished Professor Ophthalmology and Education Vice President for Health Affairs, University of California Systemwide 2000-2005 Steven P. Shearing Professor of Ophthalmology, UCSF 1998-2005 Vice Chair, Department of Ophthalmology, UCSF 1998-2000 Senior Associate Dean for Admissions and Extramural Academic Programs, UCSF School of Medicine 1998-2000 Interim Associate Dean for Student Affairs 1997-1998 Professor of Ophthalmology; Associate Dean for Admissions and Student Programs, UCSF 1993-1998 Chief, Vision Care and Research Unit, Beckman Vision Center, UCSF 1991-1993 Assistant Dean, Student Affairs, UCSF 1991-1993 Associate Professor of Ophthalmology, UCSF 1987-1993 Chief, University Eye Clinic, UCSF 1979-1991 Assistant Professor of Ophthalmology, UCSF 1979-1987 EDUCATION: Harvard Business School Advanced Management Program (AMP 167) 2005 University of California, San Francisco MD 1975 Stanford University AB 1974 Sacramento City College 1967-1969 POST-GRADUATE TRAINING: Massachusetts Eye & Ear Infirmary, Harvard Medical School (Glaucoma) Sep-Dec 1981 Fellowship: UCSF 1979-1981 Residency: UCSF 1976-1979 Internship: Martin Luther King, Jr. General Hospital, Los Angeles 1975-1976 BOARD CERTIFICATIONS: American Board of Ophthalmology 1981 National Board of Medical Examiners 1976

Michael V. Drake, M.D. Curriculum Vitae

2

DIRECTORSHIPS (CURRENT) AMERICAN TALENT INITIATIVE

Member, Steering Committee 2015-present ASSOCIATION OF AMERICAN UNIVERSITIES

Member, Board of Directors 2013-2020 Chair, Membership Committee 2016-2017; 2018-2020

Member, Review Committee 2016-2019 Member, Audit and Finance Committee 2016-2018 Member, Membership Committee 2012-present Chair, Board of Directors October 2017-October 2018 Past Chair, Board of Directors October 2018-October 2019

ASSOCIATION OF PUBLIC AND LAND-GRANT UNIVERSITIES Member, Board of Directors 2010-2011 Member, Board of Directors 2014-present Secretary, Council of Presidents 2014-2015 Chair, Council of Presidents 2015-2017 Chair-Elect, Board of Directors 2017-2018 Chair, Board of Directors 2018-2019 Past Chair, Board of Directors 2019-2020 Chairman, Commission on Access, Diversity and Excellence 2011-2012

BANK OF THE WEST Member, Board of Directors 2010-present Member, Executive Committee 2010-present Member, Compensation Committee (Chair 2018-present)

Member, Nominating Committee (Chair 2018-present) 2011-present Member, Trust Committee (Chair 2016-2018) 2012-2018

BANCWEST Member, Board of Directors 2010-March 2016 (legacy BWE) Member, Board of Directors March 2016-2019 (new BWE) Member, Risk Committee 2015-March 2016 (legacy BWE) Member, Risk Committee March 2016-2019 (new BWE)

B1G 10 ATHLETIC CONFERENCE Member, Council of Presidents/Chancellors 2014-2018 Member, Executive Committee 2016-present Vice Chair, Council of Presidents/Chancellors 2018-present

BNP PARIBAS USA, INC. Member, Audit Committee July 1, 2016-present Member, Compensation Committee July 1, 2016-present

THE COMMONWEALTH FUND Chair, Board of Directors 2019-present Member, Board of Directors 2008-present

Member, Governance & Nominating Committee (Chair 2017-2019) 2008-present NATIONAL COLLEGIATE ATHLETIC ASSOCIATION

Chair, Board of Governors May 2019-present Member, Board of Directors; Executive Committee; Governance Committee. 2012-2014 Member, Board of Governors Commission to Combat Campus Sexual Violence 2016-2018 Chair, Board of Governors Ad Hoc Committee to Promote Cultural Diversity & Equity 2016-2017 Member, Division I Presidential Forum 2015-2018 Member, Division I Sport Organizational Structure Working Group 2015-2018


3

ROCK AND ROLL HALL OF FAME AND MUSEUM Member, Board of Directors 2015-present UNIVERSITY INNOVATION ALLIANCE Member, Executive Board 2014-present DIRECTORSHIPS (RECENT) ALPHA OMEGA ALPHA Honor Medical Society Member, Board of Trustees 1996-2008 President 2002-2005 ASSOCIATION OF ACADEMIC HEATH CENTERS (AAHC)

Member, Board of Trustees 2002-2008 Chair 2007-2008 Executive Committee Member 2006-2008

BIG WEST ATHLETIC CONFERENCE Member, Board of Directors 2005-June 2014 Chair 2009-2011 Vice Chair 2007-2009

CALIFORNIA HEALTHCARE FOUNDATION Member, Board of Directors 2010-March 2015 CALIFORNIA HEALTHCARE INSTITUTE Member, Board of Directors 2006-June 2014 GILEAD SCIENCES, INC Member, Health Policy Advisory Board 2008-February 2016 ORANGE COUNTY PERFORMING ARTS CENTER Member, Board of Trustees 2008-2010 TIGER WOODS LEARNING CENTER Member, Board of Directors 2009-2011

PROFESSIONAL ASSOCIATION ACTIVITIES ASSOCIATION OF AMERICAN UNIVERSITIES

Panelist, A Conversation with AAU Presidents and Chancellors January 2018 ASSOCIATION OF PUBLIC AND LAND GRANT UNIVERSITIES

Panelist, “The Age of Disruption: Navigating, Innovating, and Excelling” November 2017 AMERICAN TECHNOLOGY COUNCIL Higher education representative June 2017 ARCHIVES OF OPHTHALMOLOGY

Member, Editorial Advisory Board 2007-2012 WESTERN ASSOCIATION OF SCHOOLS AND COLLEGES

Chair, Capacity and Preparatory Review, Scripps Research Institute March 2009 AMERICAN ASSOCIATION OF MEDICAL COLLEGES (AAMC): AAMC NIH Special Action Committee Title VII Review Committee January 2004 Medical Student Admissions after Affirmative Action April 2001 Western Regional Meeting April 1999 SP-1, Prop. 209, and Medical School Admissions (presentation),

Western Regional Meeting: Student Advice (panelist) April 1998 Address to Dean’s Assistants Group, Cultural Competency in the Academic Medical Center November 1997 Panelist: Diversity and Admissions After Affirmative Action November 1997


4

Discussant: Medical School Admissions Workshop Western Regional AAMC Meeting April 1997 Keynote Address: Minority Affairs Selection Meeting/Workshop, San Diego, CA February 1996 Panelist: Professionalism in Medical Education, Western Regional GSA/MAS Meeting April 1996 Panelist: Medical Education in the 21st Century: Who do we train? What do we teach? November 1995 Panelist: Medical Student Advising, AAMC Western Regional Conference April 1994 UCSF Graduate Student Affairs/Minority Affairs Representative 1984-1987 Facilitator: Diversity, At What Price? 1991-2000 AAMC Student Representatives Meeting, Western Regional Conference April 1994

INSTITUTE OF MEDICINE Committee on Institutional and Policy-Level Strategies for Increasing the Racial and Ethnic Diversity of the U.S. Healthcare Workforce 2002-2003

WESTERN JOURNAL OF MEDICINE Member, Editorial Advisory Board 2000-2002

ALPHA OMEGA ALPHA (UCSF) Councilor, Alpha Chapter 1993-2000

AMERICAN MEDICAL ASSOCIATION: AAMC/AMA-LCME Faculty Fellow 1998 Site visit: Meharry Medical College NATIONAL ASSOCIATION OF MEDICAL MINORITY EDUCATORS

Medical Educators Conference, Keynote Address: Medical School Admissions in the 1990s March 1998 AMERICAN ACADEMY OF OPHTHALMOLOGY

American Academy of Ophthalmology Public Information Committee 1997-1998 American Academy of Ophthalmology Summer Institute, Glaucoma Section July 1992 Task Force on Educational Technology (Course Director) 1991-1992

AMERICAN BOARD OF OPHTHALMOLOGY Associate Examiner 1984-1994

INTERNATIONAL PERIMETRIC SOCIETY Educational Standards Committee 1991-1993 NATIONAL MEDICAL ASSOCIATION

Course Director, Pre-convention Symposium 1992 NATIONAL EYE INSTITUTE

Special Projects Grant Review Committee 1990, 1991 Reviewer: American Journal of Ophthalmology, Archives of Ophthalmology, Survey of Ophthalmology, Investigative Ophthalmology and Visual Science, JAMA, Ophthalmology, Glaucoma, Western Journal of Medicine, Saudi Arabian Journal of Ophthalmology, Journal of the National Medical Association

HONORS & AWARDS APLU CGA Exemplary University President in Government Relations Award May 2020 OSU Annual Staff Achievement Award Designated as “Dr. Michael V. Drake President’s Award” 2020 Champions of Health National Medical Fellowships Academic Excellence Award 2019 Doctor of Humane Letters, Honoris Causa, Princeton University 2019 University of California-Irvine Medal 2017 10th Annual King Arts Legends & Legacies Award 2017 University of California Presidential Medal 2014 Doctor of Humane Letters, Honoris Causa, Charles R. Drew University 2012 Orange County Human Relations Commission, Commendation 2010 Multicultural Alumni Hall of Fame, Stanford University 2008 Health Initiative of the Americas, Bi-national Health Pioneer Award 2008 Orange County Human Relations Commission, Commendation 2008


5

Foundation Fighting Blindness Visionary Award 2008 The California Wellness Foundation, Champions of Health Professions Diversity Award 2007 American Academy of Arts & Sciences, Election 2007 Frederick M. Roberts Award, California Legislative Black Caucus Foundation 2007 UCSF School of Medicine, White Coat Ceremony Keynote. 2004 Herbert M. Nickens Award, AAMC 2004 UCSF Gold Headed Cane Society, Speaker’s Cane 2003 UCSF School of Medicine Alumnus of the Year 2000 S. J. Kimura Teaching Award UCSF Dept. of Ophthalmology 1999 Institute of Medicine, National Academy of Sciences, Election 1998 UCSF School of Medicine White Coat Ceremony, Physicians Oath 1998 Mentor Award, UCSF/Black Students Health Alliance 1997 UCSF White Coat Ceremony, Address 1997 Clinical Teaching Award (At graduation, UCSF Class of 1995) 1995 Honor Award, American Academy of Ophthalmology 1993 Portrait Unveiling (Remarks, Unveiling), Chancellor's Retirement 1993 Nominee, Outstanding Lecture (Class of 1994 UCSF) 1992 Selected by Senior Class to Lead Physician's Oath, UCSF School of Medicine 1991 Martin Luther King, Jr., Award for University Service 1991 Nominee, Outstanding Lecture (Class of 1993 UCSF) 1991 Outstanding Service Award, Black Students' Health Alliance (BSHA) 1990 Distinguished Employee Citation, Chancellor's Office (125th Anniversary Celebration) 1990 Nominee, Outstanding Lecture, (Class of 1992 UCSF) 1988 Sigma Pi Phi Honorary Fraternity 1988 Distinguished Alumnus Award, AOA Students (Class of 1989) 1988 Outstanding Service Award, John Hale Medical Association 1988 Outstanding Service Award, Dean's Office UCSF 1988 Michael J. Hogan Award (laboratory research) 1980 Asbury Award (clinical research) 1978 Chancellor's Award for Public Service 1974 President's Undergraduate Research Fellowship (Systemwide) 1974 PUBLIC SERVICE (CALIFORNIA) Member, The California Endowment Task Force for Health Care Options in S. Los Angeles 2008-2009 Fellow, California Council on Science and Technology 2006-2008 California Health Benefit Review Program (AB 1996 implementation) 2002-2005 ACR 139 Implementation Committee, Chair 2003-2005 Member California Healthcare Workforce Commission 2002-2005 Member, California/México Commission on Science and Technology 2002-2005 Member, Steering Committee on the Future of King/Drew Medical Center 2004 King/Drew Medical Center, Chair Co-Chair Committee on The Protection of the Public Health (SSCOT) 2001-2003 SERVICE (UC SYSTEM) WASC Reaccreditation, UC Merced 2017 Co-Chair: UC Commission on the Future Access & Affordability Workgroup 2009-2014 Advisory Board Member: Migration and Health Research Center 2009-2014 Member, UC School of Global Health Board of Directors 2009-2014 University of California Commission on the Future 2009-2011 Ex-Officio Member and UC Irvine Calit2 Representative: President's Board on Science and Innovation 2005-2010


6

Member, UC School of Global Health Ad Hoc Planning Group 2008-2009 Co-Chair: California/México Health Initiative 2002-2005 California State Summer School for Mathematics and Science (COSMOS)

Advisory Board Member 2000-2005 Blue Ribbon Panel on Health Sciences Education, UC Riverside January 2004 UC Merced Planning Task Force, UCSF Representative 1998- 2000 Medical School Admissions/Diversity Task Force 1999-2000 UCLA PREP program, Keynote Address, Finishing Exercise August 1999 UC Graduate and Professional Admissions and Outreach Programs April 1999 University-Wide Coordinating Committee for Graduate and Professional School Admissions 1995-1997 Report to UC Regents: Medical School Admissions November 1994 University-Wide Task Force on Campus Community 1991-1992 Academic Senate Student Affirmative Action Committee, Chairman 1989-1991 Academic Senate Student Affirmative Action Committee, Committee Member 1987-1991 COMMENCEMENT ADDRESSES Morgan State University (scheduled 2020, postponed due to COVID-19) pending Columbus State College 2015 Charles R. Drew University 2012 Saddleback College 2011 Washington University, St. Louis, School of Medicine 2009 UCSF School of Nursing 2008 UC Berkeley School of Optometry 2003 UCSF School of Medicine 2001 UCLA School of Dentistry 2001 UCSF School of Medicine 1999 UCSF School of Medicine 1993 LEGISLATIVE TESTIMONY House Finance Committee on Higher Education March 2017 House Finance Committee on Higher Education February 2015 California Senate Hearing on Admissions re: eligibility requirements for UC April 2009 United States House of Representatives, Financial Services Committee (Frank)

re: The Role of Public Investment in Promoting Economic Growth March 2007 California Senate Health Committee Informational Hearing re: UC Irvine Medical May 2006

Programs: Diagnosis and Prescription for Accountability California Assembly Budget Subcommittee 2, Education Finance (Dymally) May 2005 California Senate Hearing on UC Admissions (Ortiz) February 2005 California Senate Hearing re: Department of Corrections (Romero) September 2004 Governor’s Hearing on California Performance Review, Long Beach CA September 2004 California State Senate Select Committee on College & University Admissions and

Outreach January 2004 California Assembly Select Committee, re: King-Drew Medical Center January 2004 United States Senate, (Judiciary) Subcommittee on Technology,

Terrorism and Government Information (Feinstein) November 2001 California Assembly: UC Medical School Admissions September 1997 California Assembly: UC Medical School Admissions March 1997 (> 200 additional legislative and agency visits, Sacramento and Washington, D.C.) 1995-present UCSF School of Medicine Student Family Network Advisor 1993-2002


7

Essential Core Curriculum Revision Committee 2000 Search Committee, Director, Academy of Medical Educators 2000 Chancellor' Executive Committee on Diversity 1999-2000 UCSF Policy Board on Student Outreach, Recruitment, Retention,

and Academic Enrichment 1997-2000 Director, UCSF School of Medicine Advising Surgery and Surgical Specialties Career Advisor, Ophthalmology 1991-1994 Student Advisor, School of Medicine 1985-2000 Faculty-Student Liaison Committee 1988-2000 Faculty Councilor, Alpha Omega Alpha Honor Medical Society, UCSF chapter 1991-2000 Faculty Student Committee on Minority Recruitment and Retention, Chair, Steering Committee, Medical Scholars Program 1985-2000 Member, Group on Student Affairs, AAMC 1985-2000 Editor, Alumni/Faculty Bulletin 1988-1990 Council 1985-2000 Executive Committee, Editorial Committee 1988-2000 Residency Selection Committee, Ophthalmology 1979-1996 Chair 1982-1983 Medical Education/Clinical Objectives Committee 1999 Search Committee (Chair): UCSF/Fresno Associate Dean 1998-99 UCSF Career Day (high school students) 1985-1988 UCSF Course Directors and Curriculum Committee Retreat 1991, 1993-1999 Welcoming Orientation Address, Entering Freshmen Class UCSF School of Medicine 1985-1999 UCSF Campus Planning Task Force 1997-98 Search Committee: UCSF Associate Dean, Student Affairs 1997 Search Committee: UCSF Associate Dean, Curricular Affairs 1997 Association of UCSF Clinical Faculty Meeting Address: Admissions After 209 and SP-1 October 1997 UCSF Faculty Leadership Retreat, Section Leader January 1994 Search Committee: (Advisory) UCSF/UCB Joint Medical Program Director Nov-Feb 1993-94 Search Committee: UCSF Sr. Vice Chancellor/Academic Affairs 1993 Search Committee: UCSF VA Associate Chief/Education 1993 Ambulatory Care Committee 1979-1993 UCSF Faculty Leadership Retreat Address / Panel Moderator January 1993 Planning Committee, 1993 School of Medicine Faculty Leadership Retreat 1992-1993 Search Committee, Dean, Graduate Division & Vice Chancellor of Student Services 1992 Planning Comm. UCSF School of Medicine Family Weekend Address: The Medical School Experience October 1992 Association of UCSF Clinical Faculty Meeting Address: Medical Education in the 90s November 1992 UCSF Department of Dermatology Faculty Retreat Address: Successful Strategies for Achieving Housestaff Diversity November 1992 Panelist, Research Opportunities for Underrepresented Minority Medical Students September 1992 Chancellor's Special Review Committee on Campus Administrative Services August 1992 Alumni/Faculty Association 1983-1992 President 1990-1991 Pathway Advisor, School of Medicine 1985-1991 Standing Screening Committee, Class of 1990 1987-1990 Executive Committee UCSF School of Medicine Facilitator, Faculty Student Support Group 1988-1990


8

Jesse C. Davis Memorial Scholarship Fundraiser, Planning Committee Chair 1988 Admissions Committee, School of Medicine 1979-1987 Chair Panel III, Member Executive Council 1982-1987 UCSF Faculty Retreat Address: Historical perspectives and current philosophy concerning minority admissions to UCSF School of Medicine 1986 Affirmative Action Day 1985 UCSF Career Day (University students) 1985 Search Committee: Nursing Director, Ambulatory Surgery Center 1985 Affirmative Action Day Committee, Co-Chair 1985 Search Committee: LPPI / Department of Psychiatry Chair 1984-1985 Panelist, Recruitment & Retention Symposium, School of Medicine representative 1985 Health Policy Group on Medical Education in the Ambulatory Environment 1985 Ambulatory Surgery Committee 1983-1985 RECRUITING FOR SCHOOLS OF MEDICINE: UCSF Minority Students Weekend 1986-2002 UC Berkeley 1993, 1994-2002 Stanford University 1986, 1987, 1989, 1993-2001 UC Santa Barbara 1996, 1997, 2000 San Diego State 1999 Harvard University 1985, 1986, 1990, 1998 UCLA 1986, 1995(x2), 1998 Xavier University 1986, 1989, 1998 Atlanta University 1990 University of Southern California 1984, 1986 San Francisco State University 1984, 1986 Howard University 1985 Johns Hopkins 1985 OTHER (partial list): American Technology Council, Advisory Board, Golden Gate Bank 1988-1992 Free Medical Clinic Black Chemical Dependency Program 1988-1990 Advisory Board, Glide Memorial Church/Haight Ashbury 1988 MEMBERSHIPS (current) Alpha Omega Alpha American Academy of Arts & Sciences American Academy of Ophthalmology Association of Academic Health Centers Blue Ridge Academic Health Group Chandler Grant Eye Society Frederick C. Cordes Eye Society Institute of Medicine, National Academies of Science National Medical Association Society of Medical Administrators MEMBERSHIPS (previous active/leadership) Alumni Faculty Association, UCSF Association for Research in Vision & Ophthalmology (ARVO)


9

John Hale Medical Association UCSF Foundation Western Glaucoma Study Club INVITED PRESENTATIONS, academic symposia (numbered by event rather than individually): @200-500 remarks each year as Ohio State president July 2014-present 210. UCI PRIME-Wide Conference January 2020 209. Keynote: Investiture of Thomas Parham, CSUDH February 2019 208. Keynote: 2018 C-Suite Awards: The Most Admired Executives in Central Ohio September 2018 207. Stanford Grand Rounds March 2018 206. Keynote: Research Universities Leading Place-Based Climate Action Initiative,

2018 Higher Education Leadership Summit February 2018 205. Keynote: National Agricultural Alumni and Development Association June 2017 204. Economic Club of Washington, D.C.: 2017 Higher Education Panel April 2017 203. Sonoma State University Inauguration of Judy K. Sakaki April 2017 202. Dean Lawrence B. Harkless Endowed Lecture:

Higher Education, Health Care and the Future of America March 2017 201. Columbus Metropolitan Club September 2016 200. City Club of Cleveland: 21st-Century Ohio State: Re-envisioning Our Land-Grant Mission February 2016 199. Patterson Land-Grant Lecture May 2015 198. National Conference on Campus Sexual Assault and Violence Keynote Presidents Panel February 2015 197. Keynote: American Association of Physicians of Indian Origin of Central Ohio (AAPI) September 2014

(@100-150 remarks each year as UCI Chancellor 2009-2014) 196. Cordes Society Annual Meeting March 2010 Michael Hogan Lecture: Social Determinants of Health 195. Glaucoma Research & Education Group 14th Annual Glaucoma Symposium February 2010 Healthcare Reform: Perspectives and Solutions 194. UC Merced Academic Innovation Symposium November 2009 193. Ernest K Goodner Memorial Lecture UCSF: Envisioning Global Health October 2008 192. Glaucoma Research & Education Group 12th Annual Glaucoma Symposium February 2008 191. Glaucoma Research & Education Group, 11th Annual Glaucoma Symposium February 2007 190. National Medical Association, Roger Mason Lecture August 2006 189. Glaucoma Research & Education Group 9th Annual Glaucoma Symposium February 2005 188. AHC Symposium on Safety Net Hospitals (moderator) July 2004 187. Lighting the Path Symposium, Texas Tech University In the Nation’s Compelling Interest April 2004 186. Glaucoma Research & Education Group, San Francisco Glaucoma, System Failures, and Society February 2004 185. Binational Forum on Migrant Policy, UC Los Angeles Address: Differences, Disparities, and Discrimination October 2003 184. UCSF Ophthalmology Grand Rounds September 2003 183. National Conference of State Legislatures Presentation: The California Health Benefits Review Program July 2003 182. William Kerr Lecture, UCSF Gold Headed Cane Society May 2003 181. California Schools of Medicine Premedical Advising Conference, UC Davis

Keynote Address March 2003 180. Foundation for Glaucoma Research Symposium Corneal Pachymetry and

Glaucoma, San Francisco February 2003 179. Charles R. Drew School of Science and Medicine, Los Angeles


10

Presidential Symposium: The Future of Medical Education January 2003 178. American Academy of Ophthalmology, Orlando October 2002 Challenge the Experts: Case Presentations in Glaucoma Management Skills Transfer Course: Combined Cataract and Glaucoma Surgery 177. Consortium of 13 Annual Meeting, Stanford University, November 2002 Address: Diversity and Excellence in Medical Education: Admissions Policies and

Procedures 176. Ernest K Goodner Memorial Lecture UCSF: September 2002 Assessing and Treating Early Glaucoma 175. COSMOS Summer School Session, UC Davis July 2002 Keynote Address: "Why You Should Consider a Career in Health Sciences?" 174. California Schools of Medicine Premedical Advising Conference, UC Berkeley Keynote Address February 2002 173. Foundation for Glaucoma Research Symposium, San Francisco, The Ocular

Hypertension Treatment Study, Preliminary Five-Year Results February 2002 172. California Schools of Medicine Premedical Advising Conference, Los Angeles

Keynote Address October 2001 171. Testimony before the U.S. Senate Subcommittee on Technology, Terrorism, and

Government Information Hearing on Germs, Toxins and Domestic Terrorist Threats November 2001 170. UC San Diego Diversity Symposium May 2001 Keynote Address: "Achieving Diversity: Challenges to the Academic Community” 169. UC Black Administrators Council; Keynote Address, Sacramento April 2001 168. Foundation for Glaucoma Research Symposium: “Detecting and Following

Patients With Early Glaucoma” San Francisco February 2001 167. UC Management and Leadership Conference, San Diego December 2000 Address: The Future of Health Sciences Education 166. UCSF Department of Medicine Grand Rounds: September 2000 The Future of Medical Education 165. Student National Medical Association Annual Meeting, Los Angeles April 2000 Keynote speaker 164. Foundation for Glaucoma Research, SF Symposium: February 2000 The Ocular Hypertension Treatment Study: What Have We Learned? 163. UCSF Ophthalmology Grand Rounds Lecture: January 2000 Medical Education: Revisited and Revised 162. University of Illinois, Chicago, Department of Medical Education 40th Anniversary

Meeting Lecture Panel Excellence through Diversity July 1999 161. UC Black Administrators Council Lake Arrowhead March 1999 Lecture: Medical School Admissions after Prop. 209 160. Glaucoma Research Foundation Annual Course, San Francisco February 1999 Lecture: Automated Perimetry Update: Making the Right Choice Experts Panel 159. American Academy of Ophthalmology, Chicago Skills Transfer Course: November 1998 Interpreting Automated Perimetry 158. Visiting Professor, University of Rochester May 1998 Lectures: Evidence Based Ophthalmology; Automated Perimetry 157. Chicanos in Health Education, California State Conference April 1998Keynote Address: The Value of a

Medical Education 156. Glaucoma Research Foundation, San Francisco February 1998Annual course lecture: Evidence Based

Ophthalmology 155. Grand Rounds, Department of Ophthalmology, UCSF 1997 (x2), 1998 154. Visiting Professor, Stanford University February 1998


11

153. American Academy of Ophthalmology, San Francisco November 1997 Lecture: Rational Use of Visual Field Testing Combined Trabecular and Cataract Surgery Course: Visual Field Interpretation 152. Glaucoma Research Foundation February 1997 151. Orbis International Post Graduate Course; Bangalore, India February 1996 Lecture: Ultrasonic Biomicroscopy in Pigmentary Glaucoma Lecture: Automated Perimetry in Glaucoma Lecture: Combined Trabeculectomy and Cataract Extraction Lecture: Post Surgical Care of the Glaucoma Patient Lecture: Diagnosis and Treatment of Ocular Hypertension Live Interactive Surgical Demonstration: Four Glaucoma Filtration Procedures, Two Laser Peripheral Irridectomies 150. Grand Rounds, Mintu Eye Hospital February 1996 Lecture: Treatment of Low Tension Glaucoma 149. Association of Technical Personnel in Ophthalmology, San Francisco December 1995 Lecture: The Ocular Hypertension Treatment Study 148. American Academy of Ophthalmology; Atlanta November 1995 Course: Small incision phacoemulsification and trabeculectomy American Association of Medical Colleges; Washington, D.C. October 1995 Lecture: Physician Race, Ethnicity, and Practice Patterns Lecture: Affirmative Action and the University of California 146. Grand Rounds, UCSF, Dept. of Ophthalmology October 1995 Lecture: UCSF Medical School Admissions: Past Practice and Future Trends 145. ALTA Eye Society, Sacramento, CA October 1995 Lecture: Modern Management of Normal Tension Glaucoma 144. Grand Rounds, UCSF, Dept. of Ophthalmology Patient Section: September 1995 Myopia and Glaucomatous Visual Field Loss 143. Harvard Med School/Mass. Eye and Ear Infirmary July 1995 Basic Science Course ("Lancaster Course") at Colby College; Waterville, ME Lecture: Automated Perimetry Lecture: Glaucomatous Optic Atrophy 142. National Medical Association; Ophthalmology Section; Atlanta July 1995 Lecture: Managing Low Tension Glaucoma 141. Pacific Coast Oto-Ophthalmologic Society, Maui June 1995 Lecture: Ocular HTN Treatment Study Lecture: Low Tension Glaucoma Lecture: Selecting Medical Students and Residents for the Future 140. Ophthalmic Symposium; San Francisco, Lecture: June 1995 Managing Glaucoma Suspects 139. Grand Rounds, UCSF Dept. of Ophthalmology May 1995 138. Ophthalmic Symposium: Cairo, Egypt April 1995 Lecture: Automated Perimetry Lecture: Low Tension Glaucoma Diagnosis and Management; Lecture: Small Incision Surgery 137. Grand Rounds; King Khalid Eye Specialist Hospital, Riyadh, Saudi Arabia: April 1995 Automated Perimetry Using Short Wavelength Stimuli April 1995 136. Ophthalmic Symposium; Jeddah and Riyadh, Saudi Arabia Lecture: Combined Phaco-emulsification and trabeculectomy 135. Saudi Arabian Glaucoma Society, Riyadh, Saudi Arabia (Guest of Honor) April 1995 Papers: Visual Field and Optic Disc Changes in Normal Tension Glaucoma; The Use of Calcium Channel Blockers in Normal Tension Glaucoma; Treating Ocular Hypertension


12

134. Satellite Panel Discussion (US - Saudi Arabia): April 1995 Modern Management of Low Tension Glaucoma 133. Jules Stein Symposium, UCLA April 1995 Papers: Calcium Channel Blockers in Normal Tension Glaucoma; Automated Perimetry Update: New Software and Short Wavelength Perimetry 132. Medical Effectiveness Research Center, Monthly Conference March 1995 131. Grand Rounds, UCSF Department of Dermatology: March 1995 Selecting the Best Medical Students 130. Grand Rounds, Cal Pacific Medical Center, San Francisco January 1995 Lecture: Short Wavelength Photoreceptor Sensitivity in Early Glaucoma Lecture: The Ocular Hypertension Treatment Study Lectures 1-129 1979-1994 GRANTS (recent) Grants at UC-Irvine (as principal investigator) UCSF Professorship Grants HRSA/Hispanic Center of Excellence $1,698,000 PI 2001-2006 HPPI for UCSF Fresno Latino Center $349,982 PI 2002-2005 California Endowment, Planning & Initial Funding, PRIME-LC $650,000 PI 2004 California Wellness Foundation $250,000 PI 2002-2004 California Endowment, Diversity in Medical Education $4,280,000 PI 2001-2004 NEI: Ocular Hypertension Treatment Study $423,000 PI 1999-2004 California Alliance for Minority Participation $125,000 PI NEI: Ocular Hypertension Treatment Study $2,470,000 PI 1994-2006 Legislative Post Baccalaureate Recruitment 5% $112,500 PI 1999

GRANTS (previous)

NIH MEDTEP [MERC] (10% effort, investigator) $3,750,000 (direct) 1993-1998 That Man May See, Inc. HFA for OHTS study (EY10461) $27,000 PI 1993 NEI 20% (grant[suppl] R01 Ey07642-04S1) $61,000 (direct) 1991-1993 Allergan Inc. Responses to Glauc. Meds. in Black Patients $20,000 PI 1990-1992 Bausch & Lomb. Metapranolol for Glaucoma $24,000 PI 1986-1988 Johnson & Johnson: Thymoxamine in Pigmented Eyes $36,000 PI 1987 Glaucoma Research Foundation: Filtering Seton Implants $200,000 Co-PI 1984-1987 Allergan. Flubuprofen in Laser Trabeculoplasty (investigator) $3,000 1982-1984 UCSF Academic Senate Fellowship $19,000 1979-1981


13

BIBLIOGRAPHY

ARTICLES 1. Schatz H, Drake MV: Self-injected retinal emboli. Ophthalmology 86:468-483, 1979. 2. Drake MV, O'Donnell JJ, Sandman RP: Analysis of commercial pilocarpine preparations with HPLC. J

Pharm Sci 71:358, 1982. 3. O'Donnell JJ, Sandman RP, Drake MV: Measurement of pilocarpine and its degradation products by

high-performance liquid chromatography. J Pharm Sci 69:1097, 1980. 4. Drake MV: Complications of argon laser trabeculoplasty. Trans Pac Coast Oto-Ophthalmol Soc 64:71,

1983. 5. Weinreb RN, Drake MV: Treatment parameters with argon laser trabeculoplasty. Trans Pac Coast Oto-

Ophthalmol Soc 64:75, 1983. 6. Weinreb RN, Robin AL, Baerveldt G,. Drake MV, Blumenthal M, Wilensky J: Fluorobiprofen

pretreatment in argon laser trabeculoplasty for primary open-angle glaucoma. Arch Ophthalmol 102:11, 1984.

7. Drake MV, O'Donnell JJ, Polansky J: Muscarinic binding affinity of isopilocarpine. J Pharm Sci

75(3):278, 1986. 8. Drake MV: The intraocular pressure response to Neodymium YAG laser capsulotomy: Aphakic vs.

pseudophakic eyes. Ophthal Laser Surg 2(1):19-22, 1987. 9. Drake MV: Neodymium:YAG laser iridotomy. Surv Ophthalmol 32:171, 1987. 10. Hoskins HD, Magee SD, Drake MV, Kidd MN: Confidence intervals for change in automated visual

fields. Br J Ophthalmol 72(8): 591-597, 1988. 11. Drake MV (Ed): Glaucoma Update, International Ophthalmology Clinics, vol 30, no 3, p 193, 1990. 12. Drake MV: Glaucomatous visual loss: Fields, color, contrast. Int Ophthalmol Clin 30:193, 1990. 13. Hoskins HD, Iwach A, Drake MV: Subconjunctival THC:YAG laser sclerostomy ab externo in the rabbit.

Ophthalmic Surg 21:589, 1990. 14. Wright MM, Skuta GL, Drake MV et al: Time course of thymoxamine reversal of phenylephrine

mydriasis. Arch Ophthalmol 108:1729, 1990. 15. Iwach AG, Drake MV, Hoskins HD, Schuster Bl, Vassiliadis A, Crawford JB, Hennings D: A new

contact Holmium:YAG laser for cyclophotocoagulation. Ophthalmic Surg 22:345, 1991.


14

16. Hoskins HD, Iwach AG. Vassiliades A, Drake MV, Hennings MS: Subconjunctival THC:YAG laser

thermal sclerostomy. Ophthalmology 98:1394-1400, 1991. 17. Wilson MR, Drake MV: Glaucoma in Blacks: Epidemiology and management. Clinical Signs in

Ophthalmology, Vol XIII No. 2:2-16, 1992. 18. Drake MV: Complications of Glaucoma Filtration Surgery. International Ophthalmology Clinics 1992

Fall, 31(4):115-130. 19. Drake MV, Iwach A, Hoskins HD: Holmium laser sclerostomy. Exp Eye Res 55:27 (Suppl), 1992. 20. Hoskins DH, Drake MV, Minckler DH: Filtering seton implant surgery for glaucoma: An animal trial.

Ophthalmic Surg 23:702-708, 1992. 21. Iwach AG, Hoskins HD, Drake MV et al: Subconjunctival THC:YAG (Holmium) laser thermal

sclerostomy ab externo. Ophthalmology 100:356-366, 1993. 22. Drake MV, Wilson MR: Levobunolol compared to dipivifrin b.i.d. in treatment of African American

patients with open angle glaucoma. J Ocular Pharmacol 9:91-95, 1993. 23. Iwach AG, Hoskins HD, Drake MV, Dickens CJ. Update of the subconjunctival THC:YAG (holmium)

laser sclerostomy ab externo clinical trial: 30-month report. Ophthalmic Surg 1994; 25:13-21 24. Komaromy, M; Grumbach, K; Drake, M; Vranizan, K; Lurie, N; Keane, D; Bindman, AB. The role of

black and Hispanic physicians in providing health care for underserved populations [see comments]. New England Journal of Medicine, 1996 May 16, 334(20):1305-10

25. Drake, MV. New medical therapies for glaucoma. International Ophthalmology Clinics, 1996 Spring,

36(2):53-60. 26. Iwach, AG; Hoskins, HD Jr; Mora, JS; Dickens, CJ; Drake, MV; Gaffney, MM; Nguyen, N; Wong, PC;

Tran, H; Ma, AS. Update on the subconjunctival THC:YAG (holmium) laser sclerostomy Ab externo clinical trial: a 4-year report. Ophthalmic Surgery and Lasers, 1996 Oct, 27(10):823-31

27. Drake, MV; Lowenstein, DH. The role of diversity in the health care needs of California. Western

Journal of Medicine, 1998 May, 168(5):348-54. 28. Dorr, D, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Graphically

conquering the SF-36: A tool for illustrating subscale by group over time using SAS/GRAPH(r) Software. Proceedings of the twenty-third SAS Users Group International Conference: 856-859, 1998.

29. Gordon, MO., and the Ocular Hypertension Treatment Study (OHTS) Group: The Ocular Hypertension

Treatment Study, Design and Baseline Description of the Participants. Archives of Ophthalmology, Volume 117, 1999 May, 573-583.

30. Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MA for the Ocular Hypertension Study

Group. Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). Arch Ophthalmol 118:1187-1194, 2000


15

31. Piltz J, Gross, R, Shin DH, Beiser JA, Dorr DA, Kass MA, Gordon MO and the OHTS Study Group. Contralateral effect of topical ß-adrenergic antagonists in initial one-eyed trials in the Ocular Hypertension Treatment Study. Am J Ophthalmol 130:441-453, 2000

32. Brandt JD, Beiser JA, Gordon MO, Kass MA and the OHTS Group. Central Corneal thickness in the

Ocular Hypertension Treatment Study (OHTS). Ophthalmology 108:1779-1788, 2001 33. Feuer WJ, Parrish RK, II, Schiffman JC, Anderson DR, Budenz DL, Wells MC, Hess, DJ, Kass MA,

Gordon MO, and the OHTS Group. The Ocular Hypertension Treatment Study: Reproducibility of cup/disc ratio measurements over time at an Optic Disc Reading Center. Am J Ophthalmol 122:19-28, 2002

34. Johnson CA, Keltner JL, Cello KE, Kass MA, Gordon MO, Budenz DL, Gaasterland DE, Werner E, and

the Ocular Hypertension Treatment Study (OHTS). Baseline visual field characteristics in the Ocular Hypertension Treatment Study. Ophthalmology 109:432-437, 2002

35. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish, RK, Wilson MR,

Gordon MO for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open angle glaucoma. Arch Ophthalmol 120:701-713, 2002

36. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP,

Parrish RK, Wilson MR, Kass MA for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open angle glaucoma. Arch Ophthalmol 120:714-720, 2002

37. Keltner JL, Johnson CA, Cello KE, Edwards MA, Bandermann SE, Dass MA, Gordon MO for the Ocular

Hypertension Treatment Study Group. Classification of visual field abnormalities in the Ocular Hypertension Treatment Study. Arch Ophthalmol 2003; 121:643-650

38. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Coleman AL, Piltz-Seymour JR, Liebmann

JM, Cioffi GA, Trick G, Brandt JD, Gordon MO, Kass MA for the Confocol Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Racial differences in optic disc topography: Baseline results from the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Arch Ophthalmol 2004; 122:22-28.

39. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Liebmann JM, Brandt JD, Trick G, Cioffi

GA, Coleman AL, Piltz-Seymour JR, Gordon MO, Kass MA for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study: Study design and baseline factors. Am J Ophthalmol 2004; 137:219-227.

40. Higginbotham EJ; Gordon MO; Beiser JA; Drake MV; Bennett GR; Wilson MR; Kass MA; for the

Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: Topical Medication Delays or Prevents Primary Open-angle Glaucoma in African American Individuals Arch Ophthalmol, Jun 2004; 122: 813-820.

41. Coleman AL, Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study (OHTS)

Group. Baseline risk factors for the development of POAG in the Ocular Hypertension Treatment Study. Am J Ophthalmol 2004; 138(4):684-5.


16

42. Brandt JD, Beiser JA, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Central corneal thickness and measured IOP response to topical ocular hypotensive medication. Am J Ophthalmol 2004; 138:717-722

43. Hernández MT, Lemp GF, Castañeda X, Sanchez M, Aoki B, Tapia-Conyer R, Drake MV. HIV/AIDS

Among Mexican Migrants and Recent Immigrants in California and México, JAIDS, Vol. 37, Supp. 4, S203, November 2004

44. Kass MA, Gordon MO, Kymes SM for the Ocular Hypertension Treatment Study (OHTS) Group.

Incorporating the results of the Ocular Hypertension Treatment Study into clinical practice. Letter to Editor. Arch Ophthalmol 2005;123:1021-22. PMID:16009857.

45. Keltner JL, Johnson CA, Levine RA, Fan JJ, Cello KE, Kass MA, Gordon MO for the Ocular

Hypertension Treatment Study Group (OHTS). Normal visual field test results following glaucomatous visual field endpoints in the Ocular Hypertension Treatment Study. Arch Ophthalmol 2005;123:1201-06. PMCID:1828122.

46. Zangwill LM, Weinreb RN, Beiser JA, Berry CC, Cioffi GA, Coleman AL, Trick G, Liebmann JM,

Brandt JD, Piltz-Seymour JR, Dirkes KA, Vega S, Kass MA, Gordon MO for the Confocal Scaning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study Group. Baseline topographic optic disc measurements are associated with the development of primary open angle glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Arch Ophthalmol 2005;123:1188-97. PMID:16157798.

47. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz M-C, Vandenbroucke

R, Kass MA, Gordon MO, the Ocular Hypertension Treatment Group: Test-retest Reproducibility of Optic Disk Deterioration Detected From Stereophotographs by Masked Graders. Am J Ophthalmol 2005;140:762-64. PMID:16226544.

48. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO, and the Ocular Hypertension Treatment

Study (OHTS) Group. Management of ocular hypertension: A cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol 2006;141:997-1008. PMCID:1775049.

49. Levine RA, Demirel S, Fan J, Keltner JL, Johnson CA, Kass MA and the Ocular Hypertension Treatment

Study (OHTS) Group. Asymmetries and visual field summaries as predictors of glaucoma in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2006;47:3896-3903. PMCID:1995656.

50. Keltner JL, Johnson CA, Anderson DR, Levine RA, Fan JJ, Cello KE, Quigley HA, Budenz DL, Parrish

II RK, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group. The Association between Glaucomatous Visual Fields and Optic Nerve Head Features in the OHTS. Ophthalmology 2006;113:1603-12. PMID:16949445.

51. Herman DC, Gordon MO, Beiser JA, Chylack Jr. LT, Lamping KA, Schein OD, Soltau JB, Kass MA.

Topical ocular hypotensive medication and lens opacification: Evidence from the Ocular Hypertension Treatment Study (OHTS). Am J Ophthalmol 2006;142:800-12. PMCID:1976472.

52. Budenz DL, Anderson DR, Feuer WJ, Beiser JA, Schiffman J, Parrish II RK, Piltz-Seymour JR, Gordon

MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. Ophthalmology 2006;113:2137-43. PMCID:1995568.


17

53. The Ocular Hypertension Treatment Study (OHTS) Group and the European Glaucoma Prevention Study

(EGPS) Group. A validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 2007;114:10-19. PMCID:1995665.

54. Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA and the Ocular

Hypertension Treatment Study (OHTS) Group. Comparison of initial intraocular pressure response to topical beta-adrenergic antagonists and prostaglandin analogues in African Americans and whites in the Ocular Hypertension Treatment Study (OHTS). Arch Ophthalmol 2007;125:454-9. PMID:17420364

55. Keltner JL, Johnson CA, Cello KE, Bandermann SE, Fan JJ, Levine RA, Kass MA, Gordon MO and the

Ocular Hypertension Treatment Study (OHTS) Group. Visual field quality control in the Ocular Hypertenstion Treatment Study (OHTS). J Glaucoma. J Glaucoma 2007;16:665-9. PMID:18091452

56. Hernández MT, Lemp GF, Castañeda X, Sanchez M, Aoki B, Hanson J, Magis-Rodriguez C, Drake MV.

The Effect of Migration on HIV High-Risk Behaviors among Mexican Migrants, JAIDS, November 2007 57. Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study Group. Is a history of

diabetes mellitus protective against developing primary open-angle glaucoma? Arch Ophthalmol 2008;126:280-1. PMID:18268230

58. Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA and the Ocular Hypertension

Treatment Study Group. Changes in central corneal thickness over time: the Ocular Hypertension Treatment Study. Ophthalmology. 2008;115:1550-1556. PMID:18378313.

59. Bhorade AM, Gordon MO, Wilson B, Weinrab RN, Kass MA and the Ocular Hypertension Treatment

Study Group. Variability of intraocular pressure measurements in observation participants in the Ocular Hypertension Treatment Study. Ophthalmology. 2009;116:717-724 NIHMS ID:159280.

60. Drake, MV. The Need for Diversity in Medical Education, Arch Ophthalmol, Oct 2009; 127(10):1387-

1388. MONOGRAPHS 1. Blue Ridge Academic Health Group, Advancing Value in Healthcare: The Emerging Transformational

Role of Informatics, 2008. 2. Blue Ridge Academic Health Group, Fall 2008 Policy Proposal: A United States Health Board, 2008. 3. Blue Ridge Academic Health Group, The Role of Academic Health Centers in Addressing the Social

Determinants of Health, 2010. BOOKS 1. Lieberman M, Drake MV: A Simplified Guide to Computerized Perimetry, Slack, Thorofare NJ, 1987.

Spanish Language: 1992 Italian: 1993 2. Harrington DO, Drake MV: The Visual Fields, A Textbook and Atlas of Clinical Perimetry,VI Ed, CV

Mosby, St Louis, 1990. Spanish Language: 1994 3. Lieberman M, Drake MV: Computerized Perimetry, a Simplified Guide. 2nd ed, Slack, Thorofare NJ,

1993. 4. Stamper R, Lieberman, M and Drake MV: Becker/Shaffer's Diagnosis and Treatment of the Glaucomas

7th Edition CV Mosby, 1999


18

5. (Committee Author) Smedley BD, Butler AS, Bristow LR, ed. In the Nation’s Compelling Interest:

ensuring diversity in the health care workforce/Committee on Institutional and Policy-Level Strategies for Increasing the Diversity of the US Health Care Workforce, Board on Health Sciences Policy; Institute of Medicine of the National Academies, 2004

6. Stamper R, Lieberman, M and Drake MV: Becker/Shaffer's Diagnosis and Therapy of the Glaucomas,

8th Edition, CV Mosby, 2009 BOOK CHAPTERS 1. Drake MV: Approach to Ocular Emergencies. In: Callaham M (Ed) Current Therapy in Emergency

Medicine. BC Decker Inc 1987. 2. Drake MV: Approach to Ocular Emergencies. In: Callaham M (Ed) Current Therapy in Emergency

Medicine. BC Decker Inc 1987. 3. Drake MV: Visual Field Testing of Patients with Advanced Glaucoma. In: E Higginbotthom, D Lee

(Eds); Management of Difficult Glaucoma, WB Saunders 1994. 4. Drake, MV: Glaucoma. In: Rakel, RE ed; Conn's Current Therapy, WB Saunders, Philadelphia. 1997, p.

957-960. 5. Drake MV: The Glaucomatous Field. In: DM Albert, FA Jakobiec (Eds): Principles & Practice of

Ophthalmology. Chap 113. WB Saunders 1994, Second Edition: Chap 193. 1999 6. Drake MV: Field Loss in Glucoma In: Clinical Management of Glaucoma, Higginbotham E, Lee D

(Eds). 2003 ABSTRACTS 1. Kramer SG, Oyakowa R, Drake MV: Prostaglandins and the pupil. Invest Ophthalmol & Vis Res

(ARVO Suppl), April 1976. 2. Drake MV, O'Donnell JJ, Sandman RP: HPLC analysis of isopilocarpine in commercial pilocarpine.

Invest Ophthalmol & Vis Res (ARVO Suppl), April 1980, p 68. 3. Drake MV, O'Donnell JJ, Sipila I, Hopkins S: Ornithineaminotransferase activity in eye and skeletal

muscle: Hormonal regulation. Invest Ophthalmol (Suppl) 20:211, 1981. 4. Zlock D, Zumbrum A, Alvarado J, Drake MV, Polansky J: Cholinergic receptor and acetyl cholinesterase

in ciliary muscle. Invest Ophthalmol & Vis Sci (ARVO Suppl) 22, 1982. 5. Zlock D, Zumbrum A, Alvarado J, Drake MV, Polansky J: Cholinergic receptor and acetyl cholinesterase

in ciliary muscle. Invest Ophthalmol & Vis Sci (ARVO Suppl) 22, 1982. 6. Drake MV: Peripheral static testing in early glaucoma. Ophthalmology (Suppl) 94(9), 1987. 7. Drake MV, Wright MM, Skuta GL, Chang LF, Rabbani R, Teikari J, March DD: Thymoxamine reverses

phenylephrine induced mydriasis. Invest Ophthalmol & Vis Sci (Suppl) 30(3), 1989. 8. Iwach A, Drake MV, Hoskins HD. Ab externo holmium YAG laser sclerostomy in rabbits. ARVO

(Suppl) 31(3), 1990.


19

9. Hoskins HD, Drake MV, Iwach A; Transscleral cyclophotocoagulation using the holmium YAG laser.

ARVO (Suppl) 31(3), 1990. 10. Drake MV, Bosetti JB, Jameson N, Stern WH: Fibrin thrombin tissue adhesive for healing experimental

corneal perforations. ARVO (Suppl) 31(3), 1990. 11. Hoskins HD, Iwach A, Vissiliadis A, Drake MV: Subconjunctival THC:YAG (Holmium) laser thermal

sclerostomy. Ophthalmology (Suppl) 97(9):126, 1990. 12. Iwach AG, Drake MV, Hoskins HD et al: THC:YAG (Holmium) laser thermal sclerostomy ab externo.

Invest Ophthalmol & Vis Sci 33(4)(Suppl):1018, 1992. 13. Iwach AG, Drake MV, Hoskins HD et al: THC:YAG (Holmium) laser thermal sclerostomy ab externo.

Invest Ophthalmol & Vis Sci 33(4)(Suppl):1018, 1992. 14. Royal G, Drake MV, Alvarado J et al: One year follow-up of Nd:YAG contact transscleral laser

cyclophotocoagulation. Invest Ophthlamol & Vis Sci 33(4):1268. 15. Drake MV, Seiff S, Horton JR: Bilateral visual field improvement with unilateral optic nerve sheath

fenestration. Documenta Ophthalmologica (abst) Proc Xth International Perimetric Society, 1992. 16. Drake MV, Huang AS: The Tubingen electronic campimeter snowfield program for glaucoma screening.

Documenta Ophthalmologica (abst) Proc Xth International Perimetric Society, 1992. 17. Huang AS, Lieberman MF, Drake MV, Alvarado JA: Three-year follow up of Nd:YAG contact

transscleral laser cytophotocoagulation. Invest Ophthalmol & Vis Sci (Suppl) March 1994. 18. Wong, KF, Achtenberg, JF, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group:

Automated Forms of Processing: Trials, Tribulations and Triumphs. Controlled Clinical Trials 15:3S, p. 76S, 1994.

19. Gordon MO, Li Z, Schechtman KB, Kass MA, and the Ocular Hypertension Treatment Study (OHTS)

Group: Minimizing Variability and Regression to the Mean in IOP Measurements. Invest Ophthalmol Vis. Sci 36:4, S81, 1995.

20. Drake MV. Managing Low (Normal) Tension Glaucoma. J Natl Med Assn Suppl. 26-27; July 1995 21. Drake MV. Affirmative Action and University of California Med School Admission. Acad. Med. Suppl

(In Press) 22. Wong, KF, Gordon, MO, Achtenberg, JF, and the Ocular Hypertension Treatment Study (OHTS) Group:

Electronic Document Archival for a Data Coordinating Center. Controlled Clinical Trials 16:3S, p. 38S, 1995.

23. Drake, MV: Normal Tension Glaucoma. Abstract Book National Medical Association Scientific

Assembly, p. 27, 1995. 24. Gordon MO, Schechtman KB, Li Z, Kass MA, and the Ocular Hypertension Treatment Study (OHTS)

Group: A Protocol to Minimize Bias and Regression to the Mean in Measurement of Intraocular Pressure. Controlled Clinical Trials 16:3S, p. 98S, 1995

http://www.iovs.org/

http://www.iovs.org/


20

25. Gordon, MO, Johnson, CA, Spurr, JO, Kass, MA, and the Ocular Hypertension Treatment Study (OHTS)

Group: Pluses and Minuses of Relaxing Fixation Loss Criterion. Invest Ophthalmol Vis. Sci 37:3, p.S507, 1996.

26. Wong, K, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: An inexpensive

electronic system for handling adverse event reports. Controlled Clin Trial 17:2S, 1996. 27. Wong, K, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Automatic forms

processing with Windows 95: Hyperbole? Controlled Clin Trial 17:2S, 1996. 28. Kahn, JG; Drake, M; Washington, E. Cost-effectiveness of primary care-based glaucoma screening of

African Americans. Abstr Book Assoc Health Serv Res, 1997, 14:250-1. 29. Wong, K, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Electronic

systems for handling adverse event reports. Controlled Clinical Trial 18(3S):145S, 1997. 30. Bennett, GR, Cioffi, GA, Dorr, D, Gordon, MO, Beck, A, Fechtner, R, Kass, M, and the Ocular

Hypertension Treatment Study (OHTS) Group: Racial differences in response to glaucoma medications in ocular hypertensive patients. Invest Ophthalmol Vis. Sci 38(3):S278, 1997.

31. Gross, R, Piltz, J, Shin, DH, Kass, MA, Gordon, MO, and the Ocular Hypertension Treatment Study

(OHTS) Group: Contralateral effect of topical beta-blockers on intraocular pressure in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis. Sci 38(4):S1056, 1997.

32. Dorr D, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group: Graphically

conquering the SF-36: A tool for illustrating subscale by group over time using SAS/GRAPH(r) Software. Proceedings of the twenty-third Annual SAS Users Group International Conference: 856-859, 1998

33. Keltner, JL, Johnson, CA, Spurr, JO, Kass, MD, Gordon, MO, and the Ocular Hypertension Treatment

Study (OHTS) Group: Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 39(4):S493, 1998.

34. Gordon, MD, Kass, MA, Heuer, D, Higginbotham, E, Parrish, R, and the Ocular Hypertension Treatment

Study (OHTS) Group: Baseline demographics and clinical characteristics of patients enrolled in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci 39(4):S878, 1998.

35. Morris, PA, Wilder, AKA, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group:

Site visit strategies to increase collaboration of the clinic, resource centers and coordinating center. Controlled Clinical Trials 19(3S):51S, 1998.

36. Dorr, DA, Gordon, MO, and the Ocular Hypertension Treatment Study (OHTS) Group: A simple

graphical method for displaying multiple dimensions by group over time: and example using the SF-Controlled Clin Trials 19(3S)72S, 1998/

37. Fischbach E, Achtenberg J, Clark K, Tourville D, Gordon MO and the Ocular Hypertension Treatment

Study (OHTS) Group: (Under) Estimating paper storage requirements for a multicenter clinical trial. Controlled Clin Trials 19(3S):84S, 1998.


21

38. Bednarski M, Achtenberg J and the Ocular Hypertension Treatment Study (OHTS) and the Collaborative Longitudinal Evaluation of Keratoconus Study (CLEK) Groups: A quick and dirty method for delivering SAS(r) reports via the world wide web. MWSUG Conference Proceedings, 405

39. Bednarski MA, Achtenberg J and the Ocular Hypertension Treatment Study (OHTS) Group: Delivering

coordinating center reports to clinics via the world wide web. Controlled Clin Trials 20(2S):60S, 1999. 40. Wilder AK, Morris PA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS) Group:

Offering continuation education credits at clinic coordinating meeting. Controlled Clin Trials 20(2S):67S, 1999.

41. Morris PA, Wilder AK, Bednarski MA, Gordon MO and the Ocular Hypertension Treatment Study

(OHTS) Group: Accessing SAS reports by the central coordinators via the world wide web. Controlled Clin Trials 20(2S):68S, 1999.

42. Feuer WJ, Parrish RK, Wells MC, Schiffman JC, Kass MA, Gordon MO and the Ocular Hypertension

Treatment Study (OHTS) Group: Reproducibility of reading of optic disc cup/disc ratio in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 40(4):S283, 1999.

43. Keltner JL, Johnson CA, Spurr JO, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study

(OHTS) Group: Classification of visual field abnormalities in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 40(4):S69, 1999.

44. Goldstone R, Drake MV: Women of Color and the Medical School Experience. In press, Academic

Medicine 2000 45. Goldstone R, Adams M, and Drake MV: Orienting Medical Students to Diversity. In press, Academic

Medicine 2000 46. Keltner J, Johnson C, Cello K, and the Ocular Hypertension Treatment Study (OHTS) Group: Severity of

the Types of Visual Field Abnormalities in the Ocular Hypertension Treatment Study. AVRO, NANOS 2000.

47. Long E, Dunn D, Gordon M, and the Ocular Hypertension Treatment Study (OHTS) group: A

Publications and Presentation Policy for a Multicenter Clinical Trial. SCT 2000. 48. Randant D, Long E, Gordon M, the Ocular Hypertension Treatment Study (OHTS) Group. Handling

forms in a multicenter clinical trial. Control Clin Trials 21(2S): 100S, 2000. 49. Keltner JL, Johnson CA, Cello KE, Kass MA, Gordon MO, Bandermann SE, Edwards MA, Ocular

Hypertension Study Group. Visual field technician performance in the Ocular Hypertension Treatment Study (OHTS). Invest Opthalmol Vis Sci 42(4): S152, 2001.

50. Brandt JD, Beiser J, Kass MA, Gordon MO, for the OHTS Study Group. The relationship of corneal

thickness and IOP response to topical ß-blocker in the Ocular Hypertension Treatment Study. Invest Opthalmol Vis Sci 42(4): S421.

51. Wilder AK, Morris PA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS ) Group.

Improving timeliness of annual IRB approvals. Control Clin Trials 22(2S): 79S, 2001.


22

52. Bednarski MA, Beiser JA, Gordon MA, Morris PA, Wilder AK, and the Ocular Hypertension Study (OHTS) Group. Providing performance reports to clinics via the world wide web. Control Clin Trials 22(2S): 80S, 2001.

53. Morris PA, Wilder AK, Bednarski M, Gordon MO, and the Ocular Hypertension Treatment Study Group.

Omnibus clinic tracking report. Control Clin Trials 22(2S): 83S, 2001. 54. Bednarksi MA, Clark KA, Hornbeck EM, Gordon MO. Dynamic data retrieval using SAS/IntrNet. SAS

Users Group International, paper 197, April 14 55. Clark KA, Bednarski MA, Hornbeck EM, Gordon MO and the Ocular Hypertension Study Group.

Viewing case report forms on the web without scanning data. Control Clin Trials 23 (2S):40S, 2002. 56. Heuer DK, Higginbotham EJ, Kass MA, Parrish RK, Beiser JA, Gordon MO and the Ocular Hypertension

Treatment Study Group. Is there a penalty for delayed treatment in ocular hypertensives? Evidence from the Ocular Hypertension Treatment Study (OHTS). Presented at ARVO, May 4-9, 2003.

57. Achtenberg JF, Hornbeck EM, Gordon MO, and the Ocular Hypertension Treatment Study Group.

Enhanced documentation of case report forms. Control Clin Trials 24(3S):180S, 2003. 58. Bednarski MA, Achtenberg JF, Gordon MO, and the Ocular Hypertension Treatment Study Group.

Tracking and reporting multi-stage processes in a clinical trial. Control Clin Trials 24(S): 187S, 2003. 59. Kymes SM, Gordon MO, and the Ocular Hypertension Treatment Study Group. Economic evaluation in

randomized clinical trials - a promise half met? Control Clin Trials 24(3S): 187S, 2003. 60. Morris PA, Wilder AK, Gordon MO, and the Ocular Hypertension Treatment Study Group. Encouraging

participation after protocol change. Control Clin Trials 24(S)214S, 2003. 61. Keltner JL, Johnson CA, Fan J, Cello KE, Kass MA, Gordon MO and the Ocular Hypertension Treatment

Study (OHTS). Types of visual field abnormalities that subsequently become visual field primary open-angle glaucoma in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 45:E-Abstract 2134. Presented at ARVO, April 25-30, 2004.

62. Coleman AL, Gordon MO, Beiser JA, Kass MA and the Ocular Hypertension Treatment Study. A

predictive model for the development of POAG in the Ocular Hypertension Treatment Study excluding pattern standard deviation(PSD) and vertical cup/disc ratio (VC/D). Invest Ophthalmol Vis Sci 45:E-Abstract 955. Presented at ARVO, April 25-30, 2004.

63. Budenz DL, Beiser JA, Piltz JR, Parrish RK, Anderson DR, Gordon MO, Kass MA and the Ocular

Hypertension Treatment Study Group. Detection and predictive value of optic disc hemorrhages in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci 45:E-Abstract 940. Presented at ARVO, April 25-30, 2004.

64. Beiser JA, Hornbeck E, Morrison D, Gordon MO, Goldberg J. De-identification of shared datasets.

Clinical Trials 2004:1(1S):274. 65. Mansberger SL, Hughes BA, Gordon MO, Spaner SL, Beiser, JA, Cioffi GA, Kass MA and the

Ocular Hypertension Treatment Study (OHTS) Group. Comparison of IOP response to topical beta-adrenergic antagonists and prostaglandin analogues in African Americans and whites: The Ocular


23

Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci 2005;46: E-Abstract 2449. Presented at ARVO.

66. Keltner JL, Johnson CA, Cello KE, Fan J, Bandermann SE, Kass MA, Gordon MO, Beck RW and

the Ocular Hypertension Treatment Study (OHTS) group. Visual field quality control in the Ocular Hypertenstion Treatment Study and in the 10-Year Optic Neuritis Treatment Trial (ONTT) Follow-Up Study. Invest Ophthalmol Vis Sci 2005;46: E-Abstract 3738. Presented at ARVO.

67. Kass MA, Beiser JA, Herman D, Lamping K, Soltau J, Gordon MO and the Ocular Hypertension

Treatment Study Group. Is there an association of topical ocular hypotensive medication with lens opacification and visual function?: Evidence from the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2005; 46: E-Abstract 2448. Presented at ARVO.

68. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz MC, Kass MA,

Gordon MO and the Ocular Hypertension Treatment Study Group. Test-retest reproducibility of determining optic disc deterioration in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2005;46: E-Abstract 3630. Presented at ARVO.

69. Zangwill LM, Weinreb RN, Beiser JA, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Kass MA,

Gordon MO and the OHTS CSLO Ancillary Study Group. Baseline topographic optic disc measurements are associated with the development of primary open angle glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the OHTS. Invest Ophthal Vis Sci 46: E-Abstract 3631. Presented at ARVO May 1-6, 2005.

70. Keltner JL, Johnson CA, Cello KE, Fan J, Levine RA, Bandermann SE, Kass MA, Gordon MO, Beck

RW and the Ocular Hypertension Treatment Study Group. Visual Field Quality Control in the Ocular Hypertension Treatment Study (OHTS) and the Optic Neuritis Treatment Trial (ONTT). Invest Ophthal Vis Sci 2006; E-Abstract 3394. Presented at ARVO.

71. Brandt JD, Beiser JA, Gordon MO, Lin SC , Alexander MY, Kass MA and the Ocular Hypertension

Treatment Study Group. Time Dependent Changes in Central Corneal Thickness in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2006; E-Abstract 4422. Presented at ARVO.

72. Morris PA, Roediger T, Achtenberg J, Bednarski M, Clark K, Hornbeck B, Gordon MO and the

Ocular Hypertension Treatment Study (OHTS) Group. Certification,training, and support of a web-based data entry system. Clinical Trials 2006; 3:191-247. Presented at SCT.

73. Clark KA, Bednarski MA, Gordon MO and the Ocular Hypertension Treatment Study (OHTS).

Integrating adverse event data into a web-based data management. Clinical Trials 2006; 3:191-247. Presented at SCT.

74. Bandermann SE, Keltner JL, Johnson CA, Cello KE, Kass MA, Gordon MO, and Ocular

Hypertension Treatment Study Group. A Comparison Of Full Threshold and Swedish Interactive Threshold Algorithms (SITA) Testing procedures in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2007;E-Abstract 1643. Presented at ARVO.

75. Artes PH, Chauhan BC, Johnson CA, Keltner JL, Cello KE, Kass MA, Gordon MO, and Ocular

Hypertension Treatment Study Group. Longitudinal and Cross-Sectional Analyses of Visual Field


24

Progression in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2007;E-Abstract 4447. Presented at ARVO.

76. Bhorade AM, Wilson BS, Palmberg P, Miller E, Chang RT, Kass MA,Gordon MO,andOcular

Hypertension Treatment Study Group. The Predictive Accuracy of the One-Eyed Trial in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthal Vis Sci 2007; E-Abstract 5555. Presented at ARVO.

77. Achtenberg JF, Clark KA, Bednarski MA, Hornbeck EM, Gordon MO and the Ocular Hypertension

Treatment Study Group. Phased transition from traditional data entry to a web-based system. Presented at SCT May 21-24,2007.

78. Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Is a history of diabetes

mellitus (DM) protective against developing primary open-angle glaucoma (POAG)? Presented at the American Glaucoma Society, March 7, 2008.

79. Keltner JL, Johnson CA, Cello KE, Brusini P, Kass MA, Gordon MO and the Ocular Hypertension

Treatment Study Group. Application of Brusini’s Glaucoma Staging System 2 (GSS 2) to glaucomatous visual fields in the Ocular Hypertension Treatment Study. Presented at ARVO, April 27, 2008.

80. Bhorade AM, Wilson BS, Palmberg P, Miller E, Weinreb R, Kass MA, Gordon MO and the Ocular

Hypertension Treatment Study Group. Intraocular pressure variability in observation participants in the Ocular Hypertension Treatment Study. Presented at ARVO, April 28, 2008.

81. Kymes SM, Kass MA, Miller JP, Gordon MO, and the Ocular Hypertension Treatment Study Group.

The 20-year incidence of primary open-angle glaucoma among people with ocular hypertension – A decision analytic approach. Presented at ARVO, May 1, 2008.

82. Barnett EM, Fantin A, Wilson BS, Kass MA, Gordon MO and the Ocular Hypertension Treatment

Study Group. Retinal vein occlusions (RVO) in the Ocular Hypertension Treatment Study. Presented at ARVO, May 1, 2008.

83. Long EF, Dunn D, Gordon MO, the Ocular Hypertension Treatment Study group. Close-out manual

of procedures for a long-term clinical trial. Presented at the Society for Clinical Trials. May 19, 2008. 84. Gordon MO, Sarli C, Long EF, LaRue C, the Ocular Hypertension Treatment Study Group.

Assessing the impact of research. Presented at the Society for Clinical Trials, May 20, 2008.


25

MAJOR PUBLICATIONS OF THE UC OFFICE OF HEALTH AFFAIRS 1. Special Report on Medical Student Diversity, Prepared for the President of the University of California by

the Medical Student Diversity Task Force, November 2000 2. CHBRP Report 1, 2004 3. CHBRP Report 2, 2005 4. Development of Standards for use of Non-Transplant Human Anatomical Materials, prepared under the

direction of the Office of Health Affairs by Navigant Consulting, Inc. December 2004 5. Health Sciences Education: Workforce Needs and Enrollment Planning, Universitywide Health Sciences

Committee, subcommittee of the Academic Planning Council, April 2005 OTHER 1. Drake MV: Treatment Parameters for Automated Perimeters. Audio Digest 23:4, 1985. 2. Drake MV: Laser Therapy and Glaucoma. Audio Journal Review 2:8, 1986. 3. Do, D and Drake MV: Detecting Glaucoma: How to Catch the Silent Thief of Sight. UCSF J of Medical

Student Research. Spring, 1997

curriculum vitae michael v. drake, m.d. · 1 day ago · curriculum vitae . michael v. drake, m.d....

Documents